21 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
). To the Company’s knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley … , LLC during the Lock-Up Period.
4.19 Research Independence. The Company acknowledges that each Underwriter’s research analysts and research
8-K
EX-10.1
CGTX
Cognition Therapeutics Inc
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act
S-3
EX-1.2
wao8n0
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
ahn384 dwzk6fe
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
w01ifiz9f72ylz5harpv
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
auhcldbib1aq3vz7
20 Oct 22
Draft registration statement
12:00am
DEF 14A
nwr5p7a0 paxgiu3
25 Apr 22
Definitive proxy
5:28pm
10-K
wespe g92cc7civyedpi
30 Mar 22
Annual report
7:40am
10-Q
cqrfl0w hh4cc1z
17 Nov 21
Quarterly report
5:15pm
424B4
lsvot 79hzu
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
w29av a8cvggh
19 Jul 21
IPO registration
7:02am
DRS/A
nvx7gdjwejc0f
23 Jun 21
Draft registration statement (amended)
12:00am